Reduction of post-TIPS-HE through PSG-controlled TIPS-implantation

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00021157

Enrollment

120

Registered

2020-03-24

Start date

2020-06-15

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

K76.6

Interventions

Group 1: patients with liver cirrhosis and portal hypertension having an portal systemic gradient of ± 12mmHg during TIPS implantation.

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients with liver cirrhosis and indication for TIPS; written agreement; new implantation of TIPS

Exclusion criteria

Exclusion criteria: Contraindication for TIPS; TIPS implantation for other disease (non-cirrhotic portal vein thrombosis, Budd-Chiari-syndrome, nodular regenerative hyperplasia); Hepatic encephalopathy bevore TIPS = 2 (West Haven criteria); pregnancy and lactation; missing agreement; hepatocellular carcinoma; life expectancy < 12 months.

Design outcomes

Primary

Measure	Time frame
Hepatic Encephalopathy within 1 year after TIPS implantation - assessed retrospectively through medical records	—

Secondary

Measure	Time frame
Reduction of portal hypertension (ascites / varices) liver function stent function	—

Countries

Germany

Contacts

Public ContactMichael Schultheiß

Universitätsklinikum Freiburg

michael.schultheiss@uniklinik-freiburg.de0761-270-34010

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026